A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant

Psychopharmacol Bull. 2017 Sep 15;47(4):36-40.

Authors

Ryan Dammerman¹, Sonnie Kim¹, Mathews Adera¹, Alex Schwarz¹

Affiliation

¹ Drs. Dammerman, MD, PhD, Kim, PharmD, Adera, MBChB, Schwarz, PhD, Braeburn Pharmaceuticals, Princeton, NJ.

PMID: 28936007

No abstract available

Keywords: dose-ranging; pharmacokinetics; risperidone implant; schizophrenia.

Publication types

Retracted Publication